ArmaGen Technologies, a Santa Monica, CA-based developer of brain-penetrating recombinant protein therapeutics, has raised $17m in Series A funding.
The round was led by Boehringer Ingelheim Venture Fund, with participation from Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment, Inc.
Formed ArmaGen in 2004 by William M. Pardridge, MD, Chief Scientific Officer, ArmaGen Technologies has developed a platform to re-engineer recombinant proteins for BBB penetration for the treatment of diseases of the brain and spinal cord. Initially, the company will focus on orphan diseases of the CNS with lead biopharmaceuticals for Mucopolysaccharidosis (MPS) Type I, or Hurler’s syndrome and MPS Type II, or Hunter’s disease.
The company intends to use the capital for expansion of existing operations, and the clinical development of its biopharmaceuticals.
FinSMEs
03/12/2012